ID	PMID	Mutation	Gene/Protein/Region	Encoding Gene/Protein	Disease	Description	Detail
1	26849221	R397R	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
2	26849221	V429V	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
3	26849221	S474S	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
4	26849221	P476P	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
5	26849221	A487A	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
6	26849221	S492S	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
7	26849221	T524T	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
8	26849221	M563M	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
9	26849221	V574V	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
10	26849221	T585T	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
11	26849221	R594R	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
12	26849221	V595V	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
13	26849221	R397G	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
14	26849221	V429M	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
15	26849221	S474T	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
16	26849221	P476Q	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
17	26849221	A487T	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
18	26849221	S492C	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
19	26849221	T524I	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
20	26849221	M563I	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
21	26849221	V574G	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
22	26849221	T585P	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
23	26849221	R594K	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
24	26849221	V595A	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
25	26849221	Q16E	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
26	26849221	E18G	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
27	26849221	D24E	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
28	26849221	S27G	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
29	26849221	A85T	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
30	26849221	V70A	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View
31	26849221	Q74P	EBNA-1	EBNA-1	Multiple Sclerosis	R L	View

Contents
Description

The table shows all curated mutation sites of EBV in each literature

Table Description Column Note

D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.

G
The study mentioned the virus genotype/subtype information.

R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.

S
The study provided sequence information or accession numbers.

L
The study provided the geographic region/country of data origin.

C
The study provided clinical baseline information.

I
The study involved information related to immune.

T
The study involved host target genes.